Literature DB >> 18452407

A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors.

M R Namazi1, F Jowkar.   

Abstract

Proton pump inhibitors (PPI) are a group of anti-ulcer agents. PPI have selective anti-cancer effects via apoptosis of tumour, sensitization of cancer cell to chemotherapy and radiotherapy. Also PPI have anti-malarial and anti-leishmanial activity. Rising of endosomal (P)H inhibits the presentation of antigens that enter cell through endocytosis. PPI can affect transmigration of leucocytes from vessels to inflammatory sites and also can mitigate neutrophile adherence to endothelial cell. PPI increase the intralysosomal (P)H and decrease the expression of intracellular adhesion molecules. Therefore PPI can exert immunomodulation in immunological diseases through hampering antigen processing, antigen presentation, and leucocytes transmigration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452407     DOI: 10.1111/j.1365-2710.2008.00907.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  25 in total

1.  Proton pump inhibitor use and cancer mortality.

Authors:  Siri A Tvingsholm; Christian Dehlendorff; Kell Østerlind; Søren Friis; Marja Jäättelä
Journal:  Int J Cancer       Date:  2018-05-02       Impact factor: 7.396

2.  Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux.

Authors:  Jeanne-Marie Perotin; James P R Schofield; Susan J Wilson; Jonathan Ward; Joost Brandsma; Fabio Strazzeri; Aruna Bansal; Xian Yang; Anthony Rowe; Julie Corfield; Rene Lutter; Dominick E Shaw; Per S Bakke; Massimo Caruso; Barbro Dahlén; Stephen J Fowler; Ildikó Horváth; Peter Howarth; Norbert Krug; Paolo Montuschi; Marek Sanak; Thomas Sandström; Kai Sun; Ioannis Pandis; Charles Auffray; Bertrand De Meulder; Diane Lefaudeux; John H Riley; Ana R Sousa; Sven-Erik Dahlen; Ian M Adcock; Kian Fan Chung; Peter J Sterk; Paul J Skipp; Jane E Collins; Donna E Davies; Ratko Djukanović
Journal:  Eur Respir J       Date:  2019-06-27       Impact factor: 16.671

Review 3.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

4.  Associations between proton pump inhibitors and Alzheimer's disease: a nested case-control study using a Korean nationwide health screening cohort.

Authors:  Hyo Geun Choi; Joo-Hee Kim; Ji Hee Kim; Eun Soo Kim; Ha Young Park; Kyueng-Whan Min; Mi Jung Kwon
Journal:  Alzheimers Res Ther       Date:  2022-07-01       Impact factor: 8.823

Review 5.  Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.

Authors:  Ramalinga R Kedika; Rhonda F Souza; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

6.  Assessment of the potential therapeutic effects of omeprazole in Schistosoma mansoni infected mice.

Authors:  Asmaa R Ellakany; Dina I Elgendy; Hanan A Alshenawy; Amira E Abdel Ghaffar
Journal:  Parasitol Res       Date:  2019-10-26       Impact factor: 2.289

7.  A reduced esophageal epithelial integrity in a subgroup of healthy individuals increases with proton pump inhibitor therapy.

Authors:  Ans Pauwels; Charlotte Broers; Tim Vanuytsel; Nicolas Pardon; Silvia Cocca; Sabine Roman; Frank Zerbib; Jan Tack; Ricard Farré
Journal:  United European Gastroenterol J       Date:  2017-12-17       Impact factor: 4.623

8.  Lack of association between proton pump inhibitor use and decline in cognitive performance in the ELSA-Brasil cohort.

Authors:  Andrêza Soares Dos Santos; Sara Teles de Menezes; Isabela M Bensenor; Alessandra Carvalho Goulart; Sandhi Maria Barreto; Roberta Carvalho Figueiredo
Journal:  Eur J Clin Pharmacol       Date:  2021-05-20       Impact factor: 2.953

9.  Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway.

Authors:  Afshin Ebrahimpour; Min Wang; Li Li; Anil G Jegga; Mark D Bonnen; N Tony Eissa; Ganesh Raghu; Soma Jyothula; Farrah Kheradmand; Nicola A Hanania; Ivan O Rosas; Yohannes T Ghebre
Journal:  J Inflamm (Lond)       Date:  2021-05-19       Impact factor: 4.981

Review 10.  Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis.

Authors:  Sangita Biswas; Stephen H Benedict; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2012-06-07       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.